DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabECCO'16 DOP 2016
1
DOP065: Less anti-infliximab antibody formation in paediatric Crohn's patients on concomitant immunomodulatorsECCO'16 DOP 2016
1
DOP066: Disappearance of Anti-drug Antibodies to Infliximab and Adalimumab after Addition of an Immunomodulator in Patients with Inflammatory Bowel DiseaseECCO'16 DOP 2016
1
DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a Tertiary IBD CentreECCO'16 DOP 2016
1
DOP069: Dose optimization using drug and antibody levels can benefit 50% patients prescribed anti TNF therapy compared to empiric dose adjustmentECCO'16 DOP 2016
1
DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1ECCO'16 DOP 2016
1
DOP072: Association of ustekinumab trough concentrations with clinical, biochemical and endoscopic outcomesECCO'16 DOP 2016
1
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panelECCO'16 DOP 2016
1
DOP076: A Danish cross-sectional study: Autoimmune and chronic inflammatory disorders associated with Ulcerative Colitis.ECCO'16 DOP 2016
1
DOP077: Immunochip Analysis Identifies Multiple Susceptibility Loci for Collagenous ColitisECCO'16 DOP 2016
1
DOP078: Risk of malignancy in paediatric inflammatory bowel disease: Results from the DEVELOP registryECCO'16 DOP 2016
1
DOP079: Predictors of first neoplastic colonic lesion in patients with inflammatory bowel disease undergoing colonoscopic surveillanceECCO'16 DOP 2016
1
DOP081: Outcomes of Colitis-Associated Dysplasia after Referral from the Community to a Tertiary CenterECCO'16 DOP 2016
1
DOP082: PEA immunoassay technology identifies novel serum biomarkers that can diagnose and classify Inflammatory Bowel Diseases: IBD Character ConsortiumECCO'16 DOP 2016
1
DOP083: Fecal calprotectin improves the predictive power of 3 practical indices for mucosal healing among patients with Crohn’s disease: results from PREDICTECCO'16 DOP 2016
1